Safety and Efficacy of Autologous Cultured Adipocytes in Patient With Depressed Scar
A Phase II/III Clinical Study of ANTG-adip for the Treatment of Depressed Scar to Evaluate Safety and Efficacy
  • Phase

    Phase 2/Phase 3
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

Autologous cultured adipocytes (ANTG-adip) is produced by well-established techniques including cell harvesting from lipoaspirates, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label, dose-escalation study. Patients are given subcutaneous injection of ANTG-adip and followed for 12 weeks according to the clinical trial protocol.
Study Started
May 31
Study Completion
Mar 31
Last Update
Oct 09

Drug Adipocell

autologous cultured adipocytes (ANTG-adip)

autologous cultured adipocytes Experimental


Inclusion Criteria:

older than 19 years
depressed scar less than volume of 5 ml
negative for urine beta-HCG for women of childbearing age
agreement to participate, with signed informed-consent

Exclusion Criteria:

failure to meet inclusion criteria
any immune-suppressive drug, corticosteroid or cytotoxic drug within the previous 30 days
allergy to bovine-derived materials
Diagnosis of cancer, AIDS, HBV or HCV.
Patient has a lot of hairs or a tattoo on depressed site
Insufficient adipose tissue for manufacturing of ANTG-adip
Patient has depressed scar caused by a malignant tumor
Patient whom investigator consider is not suitable in this study
No Results Posted